Related Experiment Video
Updated: Jul 13, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo
Esther Arwert1, Shawn Hingtgen, Jose-Luiz Figueiredo
1Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA.
Abstract:
Many altered pathways in cancer cells depend on growth factor receptors. In primary malignant gliomas, the amplification/alteration of the epidermal growth factor receptor (EGFR) has been shown to play a significant role in enhancing glioma burden. In an effort to dissect the role of EGFR expression in glioma progression in vivo and evaluate targeted therapies for gliomas, we have genetically engineered glioma cells to visualize the dynamics of EGFR and targeted therapies in real time in vivo. Using engineered lentiviral vectors bearing fusions between EGFR and its exon 2 to 7 deleted variant (EGFRvIII) with green fluorescent protein (GFP) and Renilla luciferase (Rluc), we show that there is a direct correlation between EGFR expression and glioma cell proliferation in the initial stages of glioma progression. To monitor and evaluate EGFR-targeted therapies, we have engineered (a) short hairpin RNAs (shRNA) and (b) clinically used monoclonal antibody, cetuximab. Using EGFR-GFP-Rluc/firefly luciferase (Fluc)-DsRed2 glioma model, we show that both shRNAs and cetuximab result in a considerable reduction in glioma cell proliferation in culture and glioma burden in vivo that can be monitored in real time at a cellular resolution. This study serves as a template to follow the role of growth factor receptor expression in tumor progression and to image therapeutic efficacy of targeted therapies in cancer.
Insights
Researchers developed a new method to track epidermal growth factor receptor (EGFR) dynamics in gliomas. This technique allows real-time monitoring of EGFR-targeted therapies, showing significant reduction in glioma burden and proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Growth factor receptors, like epidermal growth factor receptor (EGFR), are crucial in cancer cell pathways.
- EGFR amplification/alteration significantly contributes to malignant glioma progression and burden.
- Understanding EGFR's role in glioma progression and evaluating targeted therapies requires advanced in vivo models.
Purpose of the Study:
- To genetically engineer glioma cells for real-time visualization of EGFR dynamics and targeted therapy efficacy in vivo.
- To dissect the role of EGFR expression in glioma progression.
- To evaluate the effectiveness of EGFR-targeted therapies in reducing glioma burden.
Main Methods:
- Engineered lentiviral vectors with EGFR and EGFRvIII fused to reporter proteins (GFP, Rluc).
- Developed a glioma model (EGFR-GFP-Rluc/Fluc-DsRed2) for in vivo imaging.
- Engineered short hairpin RNAs (shRNA) and utilized cetuximab for EGFR-targeted therapy evaluation.
Main Results:
- Demonstrated a direct correlation between EGFR expression and glioma cell proliferation in early stages.
- Showed that both shRNA and cetuximab significantly reduced glioma cell proliferation in vitro.
- Observed a considerable reduction in glioma burden in vivo using targeted therapies, monitored in real time.
Conclusions:
- The developed imaging system provides a template for studying growth factor receptor roles in tumor progression.
- Real-time monitoring of targeted therapies allows for efficient evaluation of therapeutic efficacy in gliomas.
- Genetically engineered glioma models offer powerful tools for cancer research and drug development.
